1 million SEK is granted to BioReperia to develop our model for precicion medicine read more
BioReperia is located at Linköpings University. Our researchers have more than 10 years experience developing and using zebrafish models for medical research including toxicology and tumor biology. Our models are today widely used in both academic and industrial research and drug development projects around the globe
Lasse Jensen, PhD, CTO
Lasse founded BioReperia in 2015 together with Anna Fahlgren. Lasse has long experience working with zebrafish and have set up facilities for zebrafish both at Karolinska Institute and Linköping University. In BioReperia, Lasse leads the program on advancing the use of zebrafish embryos for analysis of drug effects in vivo. Lasse has published highly on zebrafish models and are credited with developing several assay systems based on zebrafish embryos used widely for research on toxicology or tumor biology today, including the zebrafish tumor xenograft assay.
Anna Fahlgren, Docent, CEO
Anna founded BioReperia together with Lasse Jensen in 2015. Today Anna leads BioReperia´s buisness development process. Anna is an experienced researcher and have been working in one of the top ledading orthopeadic hospitals at Manhattan. Anna currently holds a position as Associate professor at Linköping University.
Anna Nilsson, PhD, CSO
Anna is responsible for sales and buisness development at BioReperia as well as leading the development of BioReperias tumor- and toxicology models. Anna holds a PhD from Linköping University in Neurobiology.
Malin Vildevall, PhD, Project leader
Malin is responsible for the R&D projects at BioReperia including managing and coordination clinical studies and cooperation’s as well as establishing and maintaining the quality assurance for new and current products. Malin holds a PhD from Linköping University in Molecular Virology and has previously worked with R&D within the medical device industry.